Global Insulin Delivery Device Market Size Study & Forecast, by Product (Reusable Insulin Pens and Disposable Insulin Pens) and End Use (Hospitals & Clinics and Homecare) and Regional Forecasts 2025-2035

The Global Insulin Delivery Device Market, valued at approximately USD 17.72 billion in 2024, is anticipated to witness a robust CAGR of 7.89% over the forecast period of 2025-2035. Insulin delivery devices—ranging from reusable to disposable pens—play a pivotal role in diabetes management by ensuring precise dosing, enhancing patient convenience, and improving treatment adherence. As diabetes prevalence surges globally due to sedentary lifestyles, urbanization, and changing dietary habits, the demand for these devices has accelerated. Moreover, increasing healthcare awareness, advancements in pen technology, and the growing preference for self-administration solutions have further propelled market expansion, positioning insulin delivery systems as indispensable tools in modern endocrinology.

The industry’s upward trajectory is further reinforced by rising investments in R&D aimed at enhancing device ergonomics, integrating digital health features, and improving portability. Growing patient adoption of smart insulin pens—equipped with Bluetooth connectivity and dose-tracking capabilities—has also opened new revenue streams for manufacturers. According to the International Diabetes Federation, over 540 million adults globally were living with diabetes in 2023, a figure projected to reach 643 million by 2030. This mounting patient base, combined with supportive reimbursement policies in developed markets and government-led diabetes management programs in emerging economies, continues to drive demand. Nevertheless, high device costs in low-income regions and the risk of product recalls may temper market growth over the coming decade.

Regionally, North America held the lion’s share of the market in 2024, driven by its advanced healthcare infrastructure, high adoption rates of innovative drug delivery technologies, and the presence of leading device manufacturers. The United States, in particular, benefits from robust insurance coverage, strong clinical research activities, and a large patient pool. Meanwhile, the Asia Pacific region is projected to record the fastest growth, supported by the rising diabetes burden in countries like China and India, expanding healthcare access, and government-backed awareness campaigns. Europe remains a significant contributor as well, with its emphasis on early diagnosis, favorable reimbursement structures, and widespread acceptance of pen-based delivery systems over traditional syringe methods.

Major market player included in this report are:
• Novo Nordisk A/S
• Sanofi S.A.
• Eli Lilly and Company
• Medtronic plc
• Becton, Dickinson and Company (BD)
• Owen Mumford Ltd.
• Ypsomed Holding AG
• Biocon Ltd.
• Companion Medical, Inc.
• Insulet Corporation
• Emperra GmbH E-Health Technologies
• Jiangsu Delfu Medical Device Co., Ltd.
• Wockhardt Ltd.
• Terumo Corporation
• HTL-STREFA S.A.

Global Insulin Delivery Device Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period – 2025-2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa



The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Product:
• Reusable Insulin Pens
• Disposable Insulin Pens

By End Use:
• Hospitals & Clinics
• Homecare

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more